XML 113 R72.htm IDEA: XBRL DOCUMENT
v3.20.2

Property and Equipment (Tables) (Brooklyn ImmunoTherapeutics, LLC) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2020 | Dec. 31, 2019
Schedule of Property and Equipment |  | Fixed assets are recorded at cost and consist of the following at December 31, 2019 and 2018:
|  | As of December 31, |
|  | 2019 |  |  | 2018 |
Site equipment |  | $ | 8,856,000 |  |  | $ | 11,566,000 |
Machinery and equipment |  |  | 1,570,000 |  |  |  | 1,887,000 |
Furniture and fixtures |  |  | 314,000 |  |  |  | 461,000 |
Leasehold improvements |  |  | 1,240,000 |  |  |  | 1,240,000 |
Vehicle |  |  | 15,000 |  |  |  | 15,000 |
|  |  | 11,995,000 |  |  |  | 15,169,000 |
Accumulated depreciation |  |  | (9,173,000 | ) |  |  | (10,502,000 | )
Total |  | $ | 2,822,000 |  |  | $ | 4,667,000 |
Brooklyn Immunotherapeutics, LLC [Member] |  |
Schedule of Property and Equipment | Property and equipment consist of the following:
|  | September 30, |  |  | December 31, |
|  | 2020 |  |  | 2019 |
Laboratory and manufacturing equipment |  | $ | 287,342 |  |  | $ | 261,164 |
Leasehold improvements |  |  | 414,504 |  |  |  | 414,504 |
|  |  | 701,846 |  |  |  | 675,668 |
Less: accumulated depreciation and amortization |  |  | (94,814 | ) |  |  | (21,905 | )
Property and equipment, net |  | $ | 607,032 |  |  | $ | 653,763 |
| Property and equipment consist of the following:
|  | December 31, |
|  | 2019 |  |  | 2018 |
Laboratory and manufacturing equipment |  | $ | 261,164 |  |  | $ | 69,597 |
Leasehold improvements |  |  | 414,504 |  |  |  | - |
|  |  | 675,668 |  |  |  | 69,597 |
Less: accumulated depreciation and amortization |  |  | (21,905 | ) |  |  | (1,498 | )
Property and equipment, net |  | $ | 653,763 |  |  | $ | 68,099 |

X
- Definition Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 + Details
Name: | us-gaap_PropertyPlantAndEquipmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |